ReviewWorld journal of gastroenterology2014
Alcoholic liver disease: treatment.
Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Intestinal microbiome-targeted therapies improve liver function in alcohol-related liver disease by restoring bifidobacteria: a systematic review and meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Hepatoprotective effect of diosmetin against thioacetamide-induced liver injury via modulating Bax/NF-κB/caspase-3/Nrf-2/PPARNaunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Indole compounds from fermented soybean products activate the aryl hydrocarbon receptor to reduce liver injury.NPJ science of food · 2025Article
- Anti-Inflammatory Drugs for Alcoholic Liver Disease: A Systematic Review on Survival and Adverse Events.International journal of hepatology · 2025Review
- Exploring the Potential Role of Massa Medicata Fermentata in Alcoholic Liver Injury Disease Based on Network Pharmacology and Animal Experiments.Combinatorial chemistry & high throughput screening · 2025Article
- Activation of pregnane X receptor sensitizes alcoholic steatohepatitis by transactivating fatty acid binding protein 4.Acta pharmaceutica Sinica. B · 2024Article
- Effects ofFoods (Basel, Switzerland) · 2024Article
- Efficacy ofHeliyon · 2024Article
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?Lipids in health and disease · 2024Review
- Comparison of the protective effects of CS/TPP and CS/HPMCP nanoparticles containing berberine in ethanol-induced hepatotoxicity in rat.BMC complementary medicine and therapies · 2024Article
- Article
- Study of Xuanhuang Pill in protecting against alcohol liver disease using ultra-performance liquid chromatography/time-of-flight mass spectrometry and network pharmacology.Frontiers in endocrinology · 2023Article
- A small HHeliyon · 2022Article
- Alcohol-Related Liver Disease: An Overview on Pathophysiology, Diagnosis and Therapeutic Perspectives.Biomedicines · 2022Review
- Oenothein B ameliorates hepatic injury in alcoholic liver disease mice by improving oxidative stress and inflammation and modulating the gut microbiota.Frontiers in nutrition · 2022Article
- "Liver-gut" axis: A target of traditional Chinese medicine for the treatment of non-alcoholic fatty liver disease.Frontiers in endocrinology · 2022Review
- Bioinformatics analysis of differentially expressed proteins in alcoholic fatty liver disease treated with recombinant human cytoglobin.Molecular medicine reports · 2021Article
- Nutritional Status and Diet Style Affect Cognitive Function in Alcoholic Liver Disease.Nutrients · 2021Article
- Alcohol-associated liver disease: A review on its pathophysiology, diagnosis and drug therapy.Toxicology reports · 2021Review
- The Role of the Gut Microbiome in Liver Cirrhosis Treatment.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The excess consumption of alcohol is associated with alcoholic liver diseases (ALD). ALD is a major healthcare problem, personal and social burden, and significant reason for economic loss worldwide. The ALD spectrum includes alcoholic fatty liver, alcoholic hepatitis, cirrhosis, and the development of hepatocellular carcinoma. The diagnosis of ALD is based on a combination of clinical features, including a history of significant alcohol intake, evidence of liver disease, and laboratory findings. Abstinence is the most important treatment for ALD and the treatment plan varies according to the stage of the disease. Various treatments including abstinence, nutritional therapy, pharmacological therapy, psychotherapy, and surgery are currently available. For severe alcoholic hepatitis, corticosteroid or pentoxifylline are recommended based on the guidelines. In addition, new therapeutic targets are being under investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.